Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04586933
Other study ID # 79907
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 10, 2020
Est. completion date June 10, 2025

Study information

Verified date January 2023
Source Haukeland University Hospital
Contact Marie N Olsen, Msc
Phone 0047-95802404
Email marienjerve@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Patients with inflammatory rheumatic diseases (IRD) are prone to malnutrition for several reasons. The diseases and treatment can cause reduced intake and absorption of nutrients and the inflammatory processes may cause an increased demand for nutrients, especially proteins. Studies report that nutritional status can affect disease activity. Dietary supplement of 3-4 gram omega-3 has shown beneficial effect upon disease activity in patients with IRD. Aim: To investigate whether improved dietary intake with and without supplements of omega-3 will affect disease activity in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Hypothesis 1: A systematic change of diet in line with the Norwegian dietary guidelines, which will result in increased intake of, among other nutrients, omega-3 fatty acids and complete protein, as well as reduced intake of saturated fat and sugar, will improve nutritional status and reduce disease activity. Hypothesis 2: A systematic change of diet (as above), included a high dose of omega-3 will further improve nutritional status and reduce disease activity compared with placebo. Design: A DB-RCT-study will be conducted. All patients will receive individualized dietary guidance by a clinical dietician for 12 weeks, before randomization to supplements of omega-3 or placebo, for 24 weeks. The supplement will be blinded for the participants, researchers and physicians. Clinical implications: The study will investigate the effect of improved diet and nutrition on treatment offered to patients with IRD to provide more evidence-based knowledge, and thus specific dietary guidelines for patients with IRD. In addition, the study might increase the understanding of the role of omega-3 in the pathogenesis of inflammation.


Description:

The study is approved by the Regional Committee for Medical and Health Research Ethics. Participation is voluntary, and informed consent will be requested. Outpatients will be recruited by doctors at the Rheumatology Department at Haukeland University Hospital (HUH). Patients recruited will be included consecutively. The recruitment period will last up to 12 months. Anthropometrical measurements, analysis of body composition, blood tests, clinical parameters, and dietary data will be collected at baseline, and after 12, 24, 36 and 52 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date June 10, 2025
Est. primary completion date June 10, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients must be diagnosed with one of the following diagnoses: rheumatoid arthritis, according to the ACR / EULAR 2010 criteria, psoriatic arthritis, according to the CASPAR criteria, axial spondylarthritis, including ankylosing spondylarthritis and non-radiographic spondylarthritis, according to the ASAS criteria - Duration of illness =0.5 years - Between 18 and 75 years - Understand Norwegian - The patient has given informed consent to participate - No change in medication the last 12 weeks before inclusion Exclusion Criteria: Diagnoses / conditions that make it difficult to follow a dietary intervention and / or supplementation of omega-3s, including: - Conditions or use of medications where omega-3 is contraindicated - Pregnancy / lactation - Allergy to soy or fish - Severe liver disease - Severe mental or physical illnesses, such as insulin-requiring diabetes

Study Design


Intervention

Dietary Supplement:
Omega-3
It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
Placebo (soya)
Placebo (soya)
Behavioral:
Dietary guidance
Dietary guidance

Locations

Country Name City State
Norway Haukeland University Hospital Bergen Vestland

Sponsors (2)

Lead Sponsor Collaborator
Haukeland University Hospital GC Rieber Oils AS

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary DAS28 (Disease Activity Score 28-joint count) Disease activity score, higher values indicate a higher disease activity and below 2.6 meaning remission. Change between week 0, 12, 24, 36 and 52
Primary ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score) Disease activity score, higher values indicate a higher disease activity Change between week 0, 12, 24, 36 and 52
Primary DAPSA (Disease Activity Index for Psoriatic Arthritis) Disease activity score, higher values indicate a higher disease activity and below 4 meaning remission Change between week 0, 12, 24, 36 and 52
Secondary RAID (Rheumatoid Arthritis Impact of Disease) Disease activity scores and scores evaluating quality of life, range 0-10, and higher scores indicate a higher grade of disability Change between week 0, 12, 24, 36 and 52
Secondary RAND12 (short form health survey) Disease activity scores and scores evaluating quality of life Change between week 0, 12, 24, 36 and 52
Secondary MHAQ (Modified Health Assessment Questionnaire) Disease activity scores and scores evaluating quality of life, range from 0 to 3 while higher values indicate a higher grade of disability Change between week 0, 12, 24, 36 and 52
Secondary BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) Disease activity scores and scores evaluating quality of life, range 0-10, and higher values indicate higher disease activity Change between week 0, 12, 24, 36 and 52
Secondary BASFI (Bath Ankylosing Spondylitis Functional Index) Disease activity scores and scores evaluating quality of life, range 0-10, and higher values indicate a higher grade of disability Change between week 0, 12, 24, 36 and 52
Secondary CDAI (Clinical Disease Activity Index) Disease activity scores and scores evaluating quality of life, range 0-76, and scores below 2.8 indicate remission Change between week 0, 12, 24, 36 and 52
Secondary Consumption of medicine after 12 months The proportion who must start or change biological treatment, use of NSAIDs and steroids Change between baseline and week 52
Secondary BMI (Body Mass Index) Nutritional status: Weight (kg) and height (m) will be combined to report BMI (kg/m^2) Change in BMI, waist circumference, fat mass (kg), fat-free mass (kg), fat-free mass index (kg/m2), fat-mass index (kg/m2), handgrip strength Change between week 0, 12, 24, 36 and 52
Secondary Waist circumference Nutritional status: Waist circumference (cm) Change between week 0, 12, 24, 36 and 52
Secondary Handgrip strength Nutritional status: Handgrip strength, measured by a dynamometer (kg) Change between week 0, 12, 24, 36 and 52
Secondary Body composition Estimation of fat mass (kg), fat-free mass (kg), measured by BIA and DXA. Fat-free mass index (kg/m2), and fat-mass index (kg/m2) will be calculated. Change between week 0, 12, 24, 36 and 52
Secondary Dietary intake of macro- and micronutrients, based on a dietary registration of 7 days Energy (E%, kcal) proteins (g and E%) ratio of fatty acids fibers (g) Vitamins and minerals Week -1,10, 50
Secondary Dietary intake of macro- and micronutrients, based on a 24h recall. Energy (E%, kcal) proteins (g and E%) ratio of fatty acids fibers (g) Vitamins and minerals Week 0, 12, 24, 36, 52
Secondary Blood lipid profile HDL (mmol/L) LDL (mmol/L) total cholesterol (mmol/L) triglycerides (mmol/L) Change from week 0, 12, 24, 36 and 52
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4